At CleanAir, nothing is more important to us than the trust you place in our solutions to help you achieve your goals. Whether you are involved in basic scientific research, drug discovery or patient care, we have proven that we have an uncompromising commitment to safety, testing, quality and craftsmanship.
Researchers have found a newer more dominant COVID-19 variant. A specific change in the virus genome of SARS-CoV-2, previously associated with increased viral transmission is now shown to be more infectious in cell culture.
CEPI has signed an agreement for the supply of glass vials to speed up the development of a COVID-19 vaccine. The partnership between Stevanato Group and CEPI sees them agree to supply 100 million Type 1 borosilicate glass vials, which will be able to hold up to two billion doses of the vaccine.
Major pharmacists are interested in the discovery of an antibody, which has been made by a group of researchers from Utrecht University and Erasmus MC. The antibody in question was left over from previous research on other coronaviruses such as SARS and MERS viruses.
As of 3rd August, there have been a total of 18,237,573 COVID-19 cases and 288,015,745 tests carried out worldwide.
Source (Cases), Source (Tests)
Make sure you join us in #SupportingScience across all of our social media channels!
Follow us on Facebook, Twitter, Instagram and LinkedIn.
1. https://www.biotecnika.org/2020/07/newer-dominant-covid-19-variant-is-more-infectious-in-the-lab-study/, 2. https://www.biopharma-reporter.com/Article/2020/06/29/Stevanato-partners-with-CEPI-for-vaccine-vials, 3. https://eindhovennews.com/corona/2020/05/major-pharmacists-interested-in-dutch-covid-19-antibody-discovery/, 4.1. https://www.statista.com/statistics/1043366/novel-coronavirus-2019ncov-cases-worldwide-by-country/, 4.2. https://www.statista.com/statistics/1028731/covid19-tests-select-countries-worldwide/
Back to News